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Abstract
Constitutive activation of signal transducer and activator of transcription 3 (STAT3) signaling is frequently detected
in cancer, promoting its emergence as a promising target for cancer treatment. Inhibiting constitutive STAT3 sig-
naling represents a potential therapeutic approach. We used structure-based design to develop a nonpeptide,
cell-permeable, small molecule, termed as LLL12, which targets STAT3. LLL12 was found to inhibit STAT3 phosphor-
ylation (tyrosine 705) and induce apoptosis as indicated by the increases of cleaved caspase-3 and poly (ADP-ribose)
polymerase in various breast, pancreatic, and glioblastoma cancer cell lines expressing elevated levels of STAT3
phosphorylation. LLL12 could also inhibit STAT3 phosphorylation induced by interleukin-6 in MDA-MB-453 breast
cancer cells. The inhibition of STAT3 by LLL12 was confirmed by the inhibition of STAT3 DNA binding activity
and STAT3-dependent transcriptional luciferase activity. Downstream targets of STAT3, cyclin D1, Bcl-2, and survivin
were also downregulated by LLL12 at both protein and messenger RNA levels. LLL12 is a potent inhibitor of cell
viability, with half-maximal inhibitory concentrations values ranging between 0.16 and 3.09 μM, which are lower than
the reported JAK2 inhibitor WP1066 and STAT3 inhibitor S3I-201 in six cancer cell lines expressing elevated levels
of STAT3 phosphorylation. In addition, LLL12 inhibits colony formation and cell migration and works synergistically
with doxorubicin and gemcitabine. Furthermore, LLL12 demonstrated a potent inhibitory activity on breast and glio-
blastoma tumor growth in a mouse xenograft model. Our results indicate that LLL12 may be a potential therapeutic
agent for human cancer cells expressing constitutive STAT3 signaling.
Neoplasia (2010) 12, 39–50
Abbreviations: DMEM, Dulbecco’s modified Eagle medium; DMSO, dimethyl sulfoxide; PARP, poly (ADP-ribose) polymerase; STAT, signal transducer and activator of tran-
scription; Tyr705, tyrosine 705
Address all correspondence to: Jiayuh Lin, Center for Childhood Cancer, The Research Institute at Nationwide Children’s Hospital, Department of Pediatrics, 700 Children’s Dr,
Columbus, OH 43205. E-mail: lin.674@osu.edu; or Chenglong Li, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, 496 W
12th Ave, Columbus, OH 43210. E-mail: cli@pharmacy.ohio-state.edu
1This research was partly funded by The Susan G. Komen Breast Cancer Foundation, The James S. McDonnell Foundation, The National Foundation for Cancer Research, and
NIHR21 grant (R21CA133652-01) to Jiayuh Lin.
2This article refers to supplementary materials, which are designated by Table W1 and Figure W1 and are available online at www.neoplasia.com.
Received 17 July 2009; Revised 8 October 2009; Accepted 9 October 2009
Copyright © 2010 Neoplasia Press, Inc. All rights reserved 1522-8002/10/$25.00
DOI 10.1593/neo.91196
www.neoplasia.com
Volume 12 Number 1 January 2010 pp. 39–50 39
Introduction
Cancer is the second leading cause of death in the United States, being
attributed to one in four deaths. Approximately one in two men and
one in three women will have their conditions diagnosed as an in-
vasive cancer in their lifetime [1]. Breast cancer is the leading type
of cancer affecting women. It is estimated that breast cancer accounts
for just more than a quarter of all newly diagnosed cancer cases in
women [1]. Pancreatic cancer is the fourth leading cause of cancer
deaths in the United States. Diagnosis is followed by a poor prognosis,
with a 5-year survival rate of only 5% [1]. Worldwide, the survival rate
for pancreatic cancer is only 1% [2]. Gliomas, a type of brain cancer,
account for more than 75% of all primary malignant brain tumors [3].
The most common type of glioma, glioblastoma, is also the most se-
vere. It is a highly aggressive cancer and continues to have a poor sur-
vival rate, with most cases becoming fatal within 2 years of diagnosis
[4,5]. The large number of cases and poor survival rates under current
therapies necessitates the search for novel target therapies for cancer.
The signal transducer and activator of transcription (STAT) pro-
teins are transcription factors that participate in relaying signals from
cytokines and growth factors [6–8]. Constitutive activation of STATs
has been found to contribute to oncogenesis [6,9]. STAT3, in partic-
ular, is constitutively active in a wide variety of human malignancies,
including breast and pancreatic cancer and glioblastoma [6–8]. STAT3
is considered to be an oncogene owing to its ability to promote ma-
lignancy [7,9,10]. Experiments have shown that constitutively active
STAT3 is sufficient for inducing cellular transformation [10]. Further
support comes from a resistance to transformation seen in STAT3-
deficient fibroblasts [11,12]. Constitutively active STAT3 has also
been shown to have the potential to alter the phenotype of nonmalig-
nant cells into one that is similar to malignant cells [13].
Persistent activation of STAT3 has been implicated in both the
induction of cancer and the processes promoting the survival of
cancer. STAT3 activation occurs when the tyrosine 705 (Tyr705) res-
idue is phosphorylated, leading to dimerization and translocation
from the cytoplasm to the nucleus [9,14,15]. In the nucleus, STAT3
binding to target genes induces the transcription and up-regulation
of proliferation and antiapoptotic associated proteins [7,9,10,16].
Therefore, constitutive STAT3 signaling is involved in stimulating
cell cycle progression and preventing apoptosis which contributes
to malignant progression [7,9]. It has also been found to promote
angiogenesis [6,17]. In addition, persistently activated STAT3 plays
a role in impairing both innate and adaptive immune responses by
enhancing immunologic tolerance and enabling cancer cells to evade
immune surveillance [18]. Further, the survival of these tumors
seems to depend on the presence of STAT3 signaling [6,11].
The implications of constitutive STAT3 signaling in tumors have
presented it as a possible target for cancer treatment. Experiments
aimed at blocking STAT3 signaling using dominant-negative STAT3,
RNA interference, and STAT3 antisense oligonucleotides have pro-
vided further evidence of the potential of STAT3 as a target for
treating cancer [6,8,19,20]. Inhibiting STAT3 using the stated ap-
proaches has been successful, resulting in an inhibition of growth
and the induction of death in tumors. It was also determined that
in normal cells, blocking STAT3 is neither harmful nor toxic to the
cells [6,11]. Given the oncogenic functions of STAT3 and the prom-
ise of inhibiting it, directly targeting STAT3 signaling represents a po-
tential therapeutic approach to treating cancer.
Using a structure-based drug design, we developed a novel STAT3
inhibitor, named LLL12. Computer models with docking simulation
showed that LLL12 binds directly to the phosphoryl tyrosine 705
(pTyr705) binding site of the STAT3 monomer. We assessed the in-
hibitory effects of LLL12 in cancer cells. We demonstrated that
LLL12 inhibits STAT3 phosphorylation (Tyr705) and STAT3 ac-
tivities; downregulates STAT3 downstream targets; inhibits prolifer-
ation, colony formation, and cell migration; and induces apoptosis in
various human breast and pancreatic cancer cells as well as in glio-
blastoma cells. We also demonstrated that LLL12 has minimal apop-
totic effects on normal human cells.
Materials and Methods
Computational Binding Studies of LLL12
Computational docking program AutoDock4 was use to dock our
designed nonpeptide small molecules and to predict their binding
modes and approximate binding free energies to STAT3 SH2 dimer-
ization site [21]. The small molecule LLL12 was docked using the
Lamarckian Genetic Algorithm. The docking procedure involved
the preparation of the ligand and macromolecule, the assignment of
Gasteiger charges, and the identification of the torsional root and
the three rotatable bonds of the ligand. An AutoGrid map was then
precomputed for all atom types in the ligand set. After 10 million
energy evaluations were completed, all the resulting conformations
of the ligand in the binding pocket of the macromolecule were clus-
tered into groups according to their conformations with a root mean
square deviation threshold of 1.5 Å. A major lowest energy cluster was
identified with 24% conformers and binding energy of −7.8 kcal/mol.
Synthesis of LLL12
Chemicals and reagents. Chemicals (except 3-hydroxy-2-pyrone,
which was purchased from Tyger Scientific, Ewing, NJ) and silica
gel were purchased from Sigma-Aldrich Chemical Co. (Milwaukee,
WI). The chemicals were checked for purity by thin layer chroma-
tography and nuclear magnetic resonance (NMR). Melting points
were determined on a Thomas Hoover capillary melting point ap-
paratus and were uncorrected. Proton nuclear magnetic resonance
spectra were obtained with a Bruker Avance 300 (300 MHz) spectro-
photometer (Billerica, MA).
Synthesis of compound 2. Naphthalene sulfonyl chloride 1 (1 g,
4.41 mmol) was dissolved in acetone (52 ml) and was stirred at 0°C
for 30 minutes. Ammonium hydroxide (52 ml) was cooled to 0°C
and was added to the above mixture and stirred at room temperature
for 3 hours. The acetone was then removed at reduced pressure. The
residue was dissolved in dichloromethane (100 ml) and washed with
water (2 × 100 ml). The organic layer was collected and evaporated
under reduced pressure. The residue was purified by silica column
chromatography (hexane–ethyl acetate, 3:1) yielding compound 2
(750 mg, 82.1%); melting point (m.p.) 147 to 149°C (literature
150°C) [22].
Synthesis of compound 3. Compound 2 (500 mg, 2.41 mmol)
was dissolved in glacial acetic acid (5.0 ml). Chromium trioxide
(1.08 g, 10.85 mmol) was dissolved in a mixture of water–glacial
acetic acid (1:1, 2 ml) and added to the solution of compound 2
in glacial acetic acid and was stirred under reflux for 15 minutes.
The solution was cooled to 0°C and water (25 ml) was added, and
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the resulting solution was stirred overnight at room temperature. The
reaction mixture was diluted with water (500 ml) and extracted with
ether (3 × 100 ml). The organic layer was collected, dried under re-
duced pressure, and purified with silica column chromatography ethyl
acetate–hexane (2:3) to yield compound 3 (88 mg, 15.4%); m.p.
(187-188°C); 1H NMR (300 MHz, dimethyl sulfoxide [DMSO])
δ 7.23 (2H, d, J = 9 Hz), 7.43 (2H, S), 8.11 (1H, t, J = 9 Hz),
8.34 (1H, d, J = 9 Hz), 8.515 (1H, d, J = 9 Hz). Mass spectrom-
etry ([M + Na]+ 260.7).
Synthesis of LLL12. A solution of compound3 (200mg, 0.843mmol)
in chloroform (14 ml) was stirred at −20°C for 10 minutes followed
by the addition of triethylamine (0.01 ml) and stirring continued at
−20°C for an additional 15 minutes. 3-Hydroxy-2-pyrone (86 mg,
0.767 mmol) dissolved in chloroform (1 ml) was added to the reaction
mixture and stirred at room temperature for 1 hour. The solvent was
removed under reduced pressure. The resulting residue was diluted
with water (50 ml), and the aqueous solution was extracted with ethyl
acetate (3 × 50 ml). The organic layer was separated, dried (brine), and
evaporated. The crude product was purified by silica column chroma-
tography (hexane–ethyl acetate, 4:1) yielding LLL12 (50 mg, 20%).
m.p. (179-181°C); 1H NMR (300 MHz, DMSO) δ 7.42-7.85
(5H, m), 8.11 (1H, m), 8.56 (2H, m), 12.05 (1H, s). Mass spectrome-
try ([M + Na]+ 326.1).
The synthesis of LLL12 began with the reaction of sulfonyl chlo-
ride 1 with ammonium hydroxide to form 2. Oxidation of 2 yielded
the naphthoquinone 3 with chromium (VI) oxide. Base-catalyzed
Diels-Alder reactions of 3-hydroxy-2-pyrone with compound 3 at
−20°C yield LLL12 and are regioisomer in a ratio of 98:2.
Cell Lines
Human breast cancer cell lines (MDA-MB-231,MDA-MB-453, and
SK-BR-3), human pancreatic cancer cell lines (HPAC and iPANC-1),
glioblastoma cell line (U87), human hepatocytes (HHs), and normal
human lung fibroblasts (WI-38) were purchased from the American
Type Culture Collection (Manassas, VA). Human glioblastoma cell line
(U373) was kindly provided by Dr. Sean Lawler (The Ohio State Uni-
versity). Human mammary epithelial cells (HMECs) were purchased
from Lonza Walkersville, Inc. (Walkersville, MD), and maintained in
Ham’s F12 medium (Mediatech, Manassas, VA) supplemented with
5 μg/ml insulin, 1 μg/ml hydrocortisone, 10 μg/ml epidermal growth
factor, 100 μg/ml cholera toxin, 5% fetal bovine serum (FBS). Immor-
talized human pancreatic duct epithelial (HPDE) cells were provided by
Dr. Ming-Sound Tsao at the University of Toronto and maintained in
CnT-07CF epidermal keratinocyte medium (CELLnTEC Advanced
Cell Systems, Bern, Switzerland) supplemented with 0.07 mM CaCl2.
TheHHs weremaintained in hepatocyte medium (ScienCell, Carlsbad,
CA) plus hepatocyte growth supplement and 5% FBS. All other cell
lines were maintained in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10% FBS, 4.5 g/L L-glutamine, sodium pyruvate,
and 1% penicillin/streptomycin. All cell lines were stored in a humidi-
fied 37°C incubator with 5% CO2.
JAK2 and STAT3 Inhibitors
LLL12, a STAT3 inhibitor, and WP1066 [23], a JAK2 inhibitor,
were synthesized in Dr. Pui-Kai Li’s laboratory (College of Pharmacy,
TheOhio State University). The powder was dissolved in sterile DMSO
to make a 20-mM stock solution. Aliquots of the stock solution were
stored at −20°C. S3I-201 [24], a STAT3 SH2 inhibitor, was pur-
chased from Calbiochem (Gibbstown, NJ).
Cell Viability Assay
Human breast cancer cell lines (MDA-MB-231 and SK-BR-3), hu-
man pancreatic cancer cell lines (PANC-1 and HPAC), and glioblas-
toma cell lines (U87 and U373) were seeded in 96-well plates at a
density of 3000 cells per well. Different concentrations of LLL12 (0.1-
10 μM), WP1066 (1-10 μM), or S3I-201 (1-100 μM) were added
in triplicate to the plates in the presence of 10% FBS. The cells were
incubated at 37°C for a period of 72 hours. 3-(4,5-Dimethylthiazolyl)-
2,5-diphenyltetrazolium bromide (MTT) viability assay was done ac-
cording to manufacturer’s protocol (Roche Diagnostics, Mannheim,
Germany). The absorbance was read at 595 nm. Half-maximal inhibi-
tory concentrations (IC50) were determined using Sigma Plot 9.0 Soft-
ware (Systat Software, Inc., San Jose, CA).
Western Blot Analysis
Human breast cancer cell lines (MDA-MB-231 and SK-BR-3), hu-
man pancreatic cancer cell lines (HPAC and PANC-1), human glio-
blastoma cell lines (U87 and U373), and human normal cells lines
(HPDE, HMEC, HH, and WI-38) were treated with LLL12 (5 or
10 μM) or DMSO at 60% to 80% confluence in the presence of
10% FBS for 24 hours, lysed in cold radio immunoprecipitation assay
lysis buffer containing protease inhibitors, and subjected to SDS-
PAGE. Membranes were probed with a 1:1000 dilution of antibodies
(Cell Signaling Technology, Beverly, MA) against phosphospecific
STAT3 (Tyr705), phosphospecific extracellular signal-regulated kinase
(ERK)1/2 (threonine 202/tyrosine 204), phosphospecific Src (tyro-
sine 416), phosphospecific themammalian target of rapamycin (mTOR)
(serine 2448), cleaved poly (ADP-ribose) polymerase (PARP), cleaved
caspase-3, cyclin D, Bcl-2, surviving, and glyceraldehyde-3-phosphate de-
hydrogenase. Membranes were analyzed using Enhanced Chemilumines-
cence Plus reagents and scanned with the Storm Scanner (Amersham
Pharmacia Biotech, Inc., Piscataway, NJ).
IL-6 Induction of STAT3 Phosphorylation
MDA-MB-453 breast cancer cells were seeded in 10-cm plates
and allowed to adhere overnight. The following night, the cells were
serum-starved. The cells were then left untreated or were treated with
LLL12 (0.5-2 μM) or DMSO. After 2 hours, the untreated and
LLL12-treated cells were stimulated by IL-6 (25 ng/ml). The cells
were harvested at 30 minutes and analyzed by Western blot.
STAT3 and STAT1 DNA Binding Activity
MDA-MB-231, SK-BR-3, HPAC, and U87 cancer cells at 60% to
80% confluence were treated with LLL12 (5 or 10 μM) or DMSO
in the presence of 10% FBS for 24 hours. A nuclear extract kit
(Clontech, Inc., Mountain View, CA) was used to obtain nuclear ex-
tracts. The nuclear extracts were analyzed for STAT3 and/or STAT1
DNA binding activity using STAT3 or STAT1 Transcription Factor
Kits (Clontech, Inc.), which provide an ELISA-based method to de-
tect DNA binding by transcription factors.
STAT3-Dependent Transcriptional Luciferase Activity
STAT3-dependent transcriptional luciferase activity was measured
using MDA-MB-231–cloned cells that stably integrate the STAT3-
dependent luciferase reporter construct, pLucTKS3 [25]. The cells
were grown in six-well plates until semiconfluent and treated in 5% FBS
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with LLL12 (1-10 μM) or DMSO for 24 hours. The luciferase assay
(Promega, Madison,WI) was run according to the manufacturer’s pro-
tocol. The STAT3 luciferase activity of the LLL12-treated cells is re-
ported relative to pLucTKS3-transfected cells treated with DMSO
arbitrarily set at 100%.
Reverse Transcription–Polymerase Chain Reaction
MDA-MB-231, HPAC, and U373 cells were treated with LLL12
(5 or 10 μM) or DMSO at 60% to 80% confluence in the presence
of 10% FBS for 24 hours. RNA from the cells was then collected
using RNeasy kits (Qiagen, Valencia, CA). Primer sequences and source
information of STAT3 downstream target genes can be found in
Table W1. Polymerase chain reaction (PCR) amplification was done
under the following conditions: 5 minutes at 94°C followed by 25 cy-
cles of 30 seconds at 94°C, 30 seconds at 55°C, and 30 seconds at 72°C
with a final extension of 5 minutes at 72°C.
Determination of Combinatorial Effects
MDA-MB-231 breast andHPAC pancreatic cancer cells were seeded
in 96-well plates in triplicate at a density of 3000 cells per well and
were treated with LLL12 (500 nM) and doxorubicin (100-400 nM,
Sigma-Aldrich, St. Louis, MO) or with LLL12 (1000 nM) and gem-
citabine (100-1000 nM, Sigma-Aldrich, St. Louis, MO) in the pres-
ence of 10% FBS. LLL12 and doxorubicin (Sigma-Aldrich, St. Louis,
MO) or LLL12 and gemcitabine (Sigma-Aldrich, St. Louis, MO)
synergy with regards to growth inhibition was determined as follows
[26]. The log ( fa/fu) was plotted against the concentration (D) for
each compound alone or in combination, where fa is the fraction
affected and fu is the fraction unaffected (1 − fa) of cells at each con-
centration. Calcusyn software (Biosoft, Ferguson, MO) was used
to determine the combinational index (CI) for each drug and con-
centration combination. ACI value of less than 1 represents synergism.
A CI value equal to 1 represents additive effects. A CI value greater
than 1 represents antagonistic effects.
Wound Healing/Cell Migration Assay
MDA-MB-231 breast cancer cells (3 × 105 per well) were seeded
in a six-well plate. Approximately 24 hours later, when the cells were
100% confluent, the monolayer was scratched using a 1-ml pipette
tip and washed once to remove nonadherent cells. New medium in
the presence of 10% FBS containing LLL12 (1-20 μM) or DMSO
was added. The treatments were removed after 4 hours, and fresh
medium was added. After an additional 20 hours without treatment,
the cells were observed under the microscope. When the wound in
Figure 1. (A) Synthesis of LLL12 (includes chemical structure). (B) Computer model of LLL12 binding to the STAT3 SH2 domain. The ball-
and-stick model of pTyr705-Leu706 is the binding mode of the partnering SH2 during the STAT3 homodimerization. LLL12 effectively
displaces its binding through stronger binding to pTyr705 binding site, indicating LLL12 can efficiently prevent STAT3 SH2 dimerization.
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the control was closed, the inhibition of migration was assessed by
using the ImageJ software, available from the National Institutes of
Health Web site (http://rsb.info.nih.gov/ij/). The percent of wound
healed was calculated using the formula: 100 − [(final area / initial
area) × 100%].
Colony Formation Assay
A base 0.6% agar gel with 10% FBS in DMEM was prepared and
added to the wells of a six-well culture dish. MDA-MB-231 breast
cancer cells were plated at a density of 5000 cells per well on top of
the base agar for anchorage-independent growth analysis in 0.4% agar
gel with 10% FBS in DMEM supplemented with LLL12 (1 or 5 μM)
or DMSO. The cells were maintained at 37°C and allowed to grow for
2 weeks. The colonies were stained using MTT dye (100 μl per well).
Pictures of the colonies were taken using a Leica MZ 16FA inverted
microscope (Leica Microsystems, Bannockburn, IL) with a 7.4 Slider
Camera (Diagnostic Instruments, Inc., Sterling Heights, MI). The col-
onies were scored by counting, and numbers were normalized as a per-
centage of colonies formed in DMSO.
Transfection with Constitutive STAT3
U87 glioblastoma cells were plated in 60-mm3 dishes or 96-well
plates. The second day, the cells were transfected using Lipofectamine
2000 (Invitrogen, Carlsbad, CA) with a vector encoding the constitu-
tive STAT3 (STAT3-C), which is tagged with the FLAG epitope [10].
Cells were treated with LLL12 (1-5 μM) or DMSO 24 hours after
Figure 2. Western blot analysis of cells treated with LLL12. Cancer cell lines expressing constitutively active STAT3, (A) MDA-MB-231,
(B) SK-BR-3, (C) HPAC, (D) U87, exhibit a decrease in the levels of expression of STAT3 phosphorylation after treatment with LLL12.
Downstream targets of STAT3, cyclin D1, Bcl-2, and survivin, were inhibited. Apoptosis is also indicated by the induction of cleaved
PARP and caspase-3. Normal cell lines that do not express elevated levels of STAT3 phosphorylation, (E) HPDE cells, HMEC, HHs, and
normal human lung fibroblasts (WI-38), did not exhibit an induction of cleaved PARP or caspase-3 after treatment with LLL12.
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transfection. Twenty-four hours later, the cells in 60-mm3 dishes were
harvested to run Western blot. Cell viability was determined by MTT
assay in 96-well plates as previously described.
Mouse Xenograft Tumor Model
MDA-MB-231 breast cancer cells (1 × 107) and U87 glioblastoma
cells (5 × 106) were injected (subcutaneously) into the right flank area of
4- to 5-week-old male athymic nude mice that were purchased from
Harlan (Indianapolis, IN). After tumor development, mice were di-
vided into three treatment groups consisting of five mice/group: DMSO
vehicle control and 2.5 and 5 mg/kg of LLL12. Tumor growth was
determined by measured the length (L) and width (W ) of the tumor
every other day with a caliper, and tumor volume was calculated on
the basis of the following formula: volume = (π/6)LW 2. After 14 days
of treatment, tumors were harvested from killed mice, snap-frozen
in liquid nitrogen, and stored at −80°C. Tumors tissue homogenates
were lysed and separated by SDS-PAGE to examine the expression of
STAT3 phosphorylation in vehicle- and LLL12-treated mice.
Results
LLL12, a Novel Small Molecule That Targets STAT3
pTyr705 is critical for the biologic function of STAT3, as it is crit-
ical for dimerization [14,15]. pTyr705 is located on a loop segment
of the SH2 domain and binds together with several adjacent amino
acid residues (leucine 706, threonine 708, and phenylalanine 710) to
a cavity on the SH2 domain of the other STAT3 monomer. We de-
signed a compound, LLL12, which binds to STAT3 SH2 domain.
The structure and synthesis of LLL12 are shown in Figure 1A. To op-
timize potency and selectivity, the main scaffold of LLL12 contains
Figure 3. LLL12 inhibits STAT3 phosphorylation induced by IL-6 in
MDA-MB-453 breast cancer cells. The cells were serum-starved
overnight, then left untreated or were treated with LLL12 (0.5-
2 μM) or DMSO. After 2 hours, the untreated and LLL12-treated cells
were stimulated by IL-6 (25 ng/ml). Thecellswere harvested at 30min-
utes and analyzed by Western blot.
Figure 4. LLL12 has an inhibitory effect on STAT3 DNA binding activity and STAT3-dependent transcriptional activity. The nuclear ex-
tracts of (A) SK-BR-3, (B) MDA-MB-231, (C) HPAC, and (D) U87 cancer cells were analyzed for STAT3 DNA binding. STAT1 DNA binding
was also looked at to demonstrate the specificity of LLL12 to STAT3 over STAT1 protein in (B) MDA-MB-231 and (D) U87 cancer cells.
Statistical significance (P < .05) relative to the DMSO vehicle control is designated by an asterisk.
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fragments that directly contact the pTyr705 binding site of STAT3
(Figure 1B). A simulated docking model shows that the sulfonamide
tail of LLL12 occupies the pTyr705 binding pocket of STAT3 with at
least three hydrogen bonds. Simulated binding energy (−7.8 kcal/mol)
of LLL12 to STAT3 predicts that it will be a potent inhibitor of the
constitutive STAT3 pathway.
LLL12 Inhibits STAT3 Phosphorylation and Induces Apoptosis
in Human Breast and Pancreatic Cancer Cells and
Glioblastoma Cells
LLL12 was evaluated for its effect on breast cancer cells (MDA-MB-
231 and SK-BR-3), pancreatic cancer cells (HPAC and PANC-1), and
glioblastoma cells (U87 and U373) that express elevated levels of
STAT3 phosphorylation. LLL12 inhibited STAT3 phosphorylation
at Tyr705 in all six cancer cell lines (Figures 2, A–D, and W1).
LLL12 was not found to inhibit phosphorylation of other kinase, such
as ERK1/2, mTOR, and Src, indicating selectivity for STAT3. As
shown in Figure 2, A–D, downstream targets of STAT3, such as cy-
clin D1, survivin, and Bcl-2 [10], were downregulated by LLL12. The
inhibition of STAT3 phosphorylation by LLL12 seems to be consis-
tent with the induction of apoptosis as evidence by the cleavages of
PARP and caspase-3 (Figures 2, A–D, and W1). The effect of LLL12
was also examined in cells that do not express elevated levels of STAT3
phosphorylation (HPDE cells, HMECs, HHs, andWI-38 normal lung
fibroblasts). LLL12 did not induce cleaved PARPor caspase-3 in any of
these cells lines (Figure 2E). This indicates that LLL12 is selective for
cancer cells expressing elevated levels of STAT3 phosphorylation.
LLL12 Inhibits STAT3 Phosphorylation Induced by IL-6
Activation of STAT3 can be induced by IL-6 [14,15]. MDA-MB-
453 breast cancer cells, which do not express persistently phosphory-
lated STAT3, were used to determine if LLL12 is capable of inhibiting
IL-6-induced STAT3 phosphorylation. We found that IL-6 stimulates
STAT3 phosphorylation in MDA-MB-453 cells. This stimulation of
STAT3 phosphorylation was blocked by LLL12 in a dose-dependent
manner (Figure 3). These results support that LLL12 is a potent in-
hibitor of STAT3 phosphorylation in cancer cells.
LLL12 Inhibits STAT3 DNA Binding
To confirm the inhibition of STAT3 signaling by LLL12, we exam-
ined the inhibition of STAT3 DNA binding activity. LLL12 caused a
statistically significant inhibition of STAT3 DNA binding activity in
breast cancer cell lines, SK-BR-3 (Figure 4A) and MDA-MB-231
(Figure 4B), pancreatic cancer cell line, HPAC (Figure 4C ), and glio-
blastoma cell line, U87 (Figure 4D). LLL12 did not inhibit STAT1
DNA binding activity (Figure 4, B and D), indicating a specificity
of LLL12 for STAT3 over STAT1.
Figure 5. (A) STAT3-dependent transcriptional activity was analyzed in a luciferase assay. MDA-MB-231 breast cancer cloned cells that
stably integrate the STAT3-dependent luciferase reporter construct, pLucTKS3, were used. Results are reported relative to a pLucTKS3-
transfected sample treated with DMSO set at 100%. Statistical significance (P < .05) relative to DMSO is designated by an asterisk. (B)
Transcription of STAT3-regulated genes is inhibited by LLL12. RT-PCR reveals decreased expression of STAT3 target genes over a
DMSO control after treatment with LLL12.
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LLL12 Inhibits STAT3-Dependent Transcriptional Activities
and Transcription of Downstream Targets of STAT3
As previously mentioned, STAT3 binding to the promoters of the
target genes induces the transcription of several proliferation- and
antiapoptotic-associated proteins. STAT3-dependent transcriptional
luciferase activity was then examined after treatment with LLL12 for
24 hours. As seen in the luciferase assay (Figure 5A), LLL12 also in-
hibited STAT3-dependent transcriptional activity in a dose-dependent
manner. To further analyze the impact of LLL12 on the inhibition of
STAT3, we looked at the transcription of downstream target genes
of STAT3 by reverse transcription (RT)–PCR. We treated MDA-
MB-231 breast cancer cells, HPAC pancreatic cancer cells, and U373
glioblastoma cells with LLL12 (5 or 10 μM) or DMSO for 24 hours.
RT-PCR was run for cyclin D1, survivin, and Bcl-XL. We found that
treatment with LLL12 resulted in an inhibition of the transcription of
STAT3-regulated genes (Figure 5B).
Inhibition of Cell Proliferation/Viability in Human Breast
and Pancreatic Cancer Cells and Glioblastoma Cells by LLL12
STAT3 activation is important for cell proliferation and survival.
Cell viability assays were run to examine the inhibitory affect of
LLL12 on human breast and pancreatic cancer cells and glioblas-
toma cells. A dose-dependent inhibition in tumor cell proliferation/
viability was seen after 72 hours of treatment. IC50 values were cal-
culated for LLL12 and other previously characterized inhibitors
(Table 1), namely, WP1066 [23], a JAK2/STAT3 inhibitor, and
S3I-201 [24], a STAT3 inhibitor. The inhibitory efficacy of the three
compounds was compared. LLL12 is substantially more potent in the
inhibition of cell viability than the other available inhibitors in all the
cell lines analyzed.
Table 1. IC50 Obtained for STAT3 Inhibitors (μM) in Human Breast, Pancreatic Cancer and
Glioblastoma.
LLL12 WP1066 S3I-201
MDA-MB-231 0.97 7.48 >100
SK-BR-3 3.09 3.31 >100
PANC-1 0.29 5.12 >100
HPAC 0.16 2.52 >100
U87 0.21 5.78 55.10
U373 0.86 5.16 52.50
All values reflect concentrations calculated after 72 hours of treatment in an MTT viability assay.
Figure 6. (A) Colony formation of MDA-MB-231 cells in soft agar is inhibited by LLL12. The potency of LLL12 was assessed further in an
anchorage-independent environment through a colony formation assay. Treatment with LLL12 greatly decreased the ability of MDA-MB-
231 cells to form colonies in comparison to a DMSO control. (B) LLL12 inhibits cell migration in MDA-MB-231 breast cancer cells. A
wound healing assay reveals that LLL12 has a significant impact on MDA-MB-231 cell migration. The ability of the cells to migrate is
increasingly inhibited by an increase in dose of LLL12. Statistical significance (P < .05) relative to the DMSO control is designated by an
asterisk. (C) A cell viability assay (MTT) was done to determine if the effect of LLL12 on MDA-MB-231 cell migration was due to its ability
to inhibit cell proliferation. The time points of treatment (4 hours with LLL12) and incubation (additional 20 hours without LLL12) used in
the wound healing assay was applied in the viability assay. The ability of LLL12 to inhibit cell migration does not seem to be due to an
inhibition of cell proliferation.
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Anchorage Independence and Cell Viability
An indicator of transformation is the ability of cells to grow in the
absence of substratum attachment [9]. Anchorage-independent
growth is vitally important in the formation of the tumor [27].
The soft agar colony formation assay provides an assessment of tu-
mor cells’ susceptibility to a drug in an anchorage-independent en-
vironment. It is considered a more sensitive measure of toxicity,
reflecting the efficacy of a drug, because it is analyzed when cells
are in a proliferative state [28,29]. We examined the effect that
LLL12’s ability to inhibit STAT3 would have on colony formation
of MDA-MB-231 cells in soft agar. Compared with the DMSO con-
trol, treatment with LLL12 led to a decrease of more than 95% in
colony formation (Figure 6A). The results of this assay further con-
firm what was seen in the MTTassay: LLL12 is a potent inhibitor for
cancer cell viability.
LLL12 Inhibits Cell Migration in MDA-MB-231 Breast
Cancer Cells
Cell migration is important in physiologic processes, such as
wound healing and tumor metastasis. To assess the effect of LLL12
on cell migration, a wound healing assay was done. After the creation
of a wound, cells were treated with various concentrations of LLL12.
Treatment was removed after 4 hours. Cells were allowed to migrate
into the denuded area for 24 hours. Treatment with LLL12 at a con-
centration of 2.5 μM or higher caused a significant decrease in cell
migration (Figure 6B). The ability of LLL12 to inhibit cell migration
may not be due to its ability to inhibit cell proliferation. MTT assay
reveals that the dosages and time points used in the migration assay
have minimal impact on cell viability (Figure 6C ).
Quantitative Combinatorial Effects between LLL12 and
Doxorubicin or Gemcitabine
We evaluated the potential of LLL12 to act in a synergistic manner
with doxorubicin or gemcitabine. MDA-MB-231 breast cancer cells
were treated with doxorubicin or LLL12. HPAC pancreatic cancer
cells were treated with gemcitabine or LLL12. The treatments lead
to a dose-dependent decrease in cellular viability. To determine the
combinatorial effects of the treatments, a constant concentration of
LLL12 was used with varying concentrations of doxorubicin or gem-
citabine. After 72 hours of treatment, a greater decrease in cell via-
bility is seen in the combination treatments (Figure 7, A and B). The
CI for each drug and concentration combination was calculated. The
CI values of all the combinations of treatments were less than 1, in-
dicating synergism between LLL12 and doxorubicin or gemcitabine.
The synergistic effects seen with LLL12 and the currently used can-
cer therapeutic agents could prove useful in cancer therapy.
Figure 7. The combinatorial effect of LLL12 and chemotherapy drugs, doxorubicin and gemcitabine. (A) MDA-MB-231 breast cancer
cells were treated with LLL12 and doxorubicin individually and in combination. (B) HPAC pancreatic cancer cells were treated with LLL12
and gemcitabine individually and in combination. Cell viability was determined by MTT assay. A synergistic effect between LLL12 and
doxorubicin or gemcitabine is indicated by an asterisk.
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Effect of the Expression of Constitutively Active STAT3 Protein
on LLL12-Mediated Inhibition
To confirm that LLL12 inhibition is indeed through the inhibition
of STAT3, U87 glioblastoma cells were transfected with a constitu-
tively active form of STAT3, STAT3-C (a murine STAT3). LLL12
(2.5 and 5 μM) inhibited STAT3 phosphorylation at Tyr705 and in-
duced apoptosis that was indicated by caspase-3 cleavage in U87 cells
(Figure 8A). However, LLL12 did not increase cleaved caspase-3 after
the U87 cells were transfected with STAT3-C expression vector
(Figure 8A). The expression of Flag-STAT3 was verified in STAT3-
C–transfected U87 but not in nontransfected U87 cells (Figure 8A).
The inhibition of cell viability of LLL12 in U87 cells was also partially
reversed by the transfection with STAT3-C expression vector (Fig-
ure 8B). Our results show that STAT3-C can at least partially rescue
LLL12-mediated inhibition. The fact that we did not observe a com-
plete rescue by STAT3-C may be due to the transfection efficiency.
Not 100% of U87 cells were transfected, and cells did not express that
STAT3-C are still sensitive to LLL12 inhibition.
LLL12 Suppresses Tumor Growth in Mouse Model In Vivo
We further investigate whether LLL12 exhibits antitumor effect
in vivo. Mouse xenograft experiments were performed by implant-
ing MDA-MB-231 breast cancer cells or U87 glioblastoma cell line
and then giving 2.5 and 5 mg/kg LLL12 or DMSO daily after tu-
mor development. As shown in Figure 9, LLL12 significantly inhibited
tumor growth compared with DMSO-treated controls in the MDA-
MB-231 (Figure 9A) and U87 xenografted mice (Figure 9B). STAT3
but not ERK1/2 phosphorylation of tumor tissue samples from these
mice was also decreased by LLL12 (Figure 9C ), suggesting that inhibi-
tion of STAT3 resulted in the suppression of tumor growth in mice.
Compound Assessments for Drug-Likeness
Drug-likeness characteristics of LLL12 were evaluated using QikProp
(Schrodinger LLC, Portland, OR). The absorption, distribution, metab-
olism, excretion, and toxicity of LLL12 were computed. Fifty “drug-
likeness” parameters were evaluated, includingmolecular weight, polarity,
solubility, cell permeability, blood-brain barrier, Human ether-a-gogo
related gene K+ blockage, human serum albumin binding, metabolic
stability, and more. LLL12 showed decent “druglike” properties. Se-
lected highlights are listed here: (1) possible in vivo metabolic reactions
range only from 1 to 3; (2) composite logP values range from −2 to 2; (3)
predicted IC50 values for HERG K
+ channels are around −3, well above
−5 for any concern; (4) predicted Caco-2 and Madin-Darby canine
kidney cell permeability values are acceptable; (5) predicted brain-blood
partition coefficients are above −3; (6) predicted index of binding to
human serum albumin ranges from −0.5 to −0.8, well within the rec-
ommended range of −1.5 to 1.5; (7) predicted human oral absorption
percentage is around 60%. Compared with existing drugs, LLL12
is 90% similar to sulfacytine and chlorthalidone. Overall, LLL12 is
worthy of medicinal chemistry research effort for further optimization.
Discussion
STAT3, a member of the STAT family of transcription factors, is an
oncogenic protein that is frequently activated in many types of cancer
Figure 8. The effect of STAT3-C expression on LLL12-mediated inhibition in U87 glioblastoma cells. Cells were transfected with a vector
expressing constitutively active STAT3, STAT3-C for 24 hours, then treated with LLL12 for another 24 hours. (A) LLL12-induced caspase-3
cleavage was rescued in U87 cells when STAT3-C protein was expressed. (B) The inhibition of cell viability of LLL12 in U87 cells was also
reduced in the presence of STAT3-C protein in MTT assay (*P < .05).
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[6–8]. STAT3 activation results in the expression of downstream
genes that promote cell proliferation and provide resistance to apop-
tosis, such as cyclin D1 and Bcl-2 respectively [7,9,10,16]. STAT3
has been classified as an oncogene because activated STAT3 can me-
diate oncogenic transformation in cultured cells and tumor forma-
tion in nude mice [10]. In contrast, STAT3-deficient fibroblasts
were shown to be resistant to transformation by a variety of onco-
genes [11,12]. Constitutive STAT3 signaling participates in onco-
genesis by stimulating cell proliferation, mediating immune evasion,
promoting angiogenesis, and conferring resistance to apoptosis in-
duced by conventional therapies [6,16,18,30]. The crucial role of
STAT3 in cancer progression and tumorigenesis has allowed STAT3
to emerge as a promising molecular target for treating cancer [6,8,9].
Previous methods aimed at blocking STAT3 have included the use of
RNA interference, STAT3 antisense oligonucleotides, and dominant-
negative STAT3 [14,19,31]. Although the stated approaches have
been successful, limitations apply to their delivery and stability [32,33].
Peptide-based inhibitors of STAT3 have also been reported, but their
use is confined by poor cell permeability and in vivo stability [34,35].
In addition, nonpeptide small-molecule inhibitors have been devel-
oped, which inhibit STAT3, including WP1066 [23], S3I-201 [24],
STA-21 [36], Stattic [37], and SD-1029 [38].
We developed a novel small-molecule STAT3 inhibitor using
structure-based design, named LLL12. We evaluated the inhibitory
efficacy of LLL12 in breast and pancreatic cancer cells and glioblas-
toma cells with constitutively active STAT3. The results demonstrate
that LLL12 is able to inhibit STAT3 phosphorylation. The inhibi-
tory effects of LLL12 for STAT3 downstream target genes result in
an inhibition of cell viability and the induction of apoptosis. Further,
LLL12 is more potent than STAT3 inhibitors that have previously
been reported, namely S3I-201 and WP1066, in the inhibition of
cancer cell viability. We also show that LLL12 works synergistically
with doxorubicin and gemcitabine in MDA-MB-231 breast and
HPAC pancreatic cells, respectively. We also found that LLL12 did
not induce detectable cleavage of caspase-3 and PARP in normal
cells, in which STAT3 is not constitutively activated. In addition,
the phosphorylation of other kinases, such as ERK1/2, mTOR,
and Src, were not found to be inhibited by LLL12, suggesting the
selectivity of LLL12 to these kinases. LLL12 inhibited STAT3 DNA
binding activity, but STAT1 DNA binding activity was not inhibited
further indicating its selectivity on STAT3 over STAT1. All these re-
sults indicate the potency and selectivity of LLL12 for STAT3, which
is derived from its direct interaction with the pTyr705 binding site of
STAT3 as predicted in our computer-generated docking model.
On the basis of our findings, treatment with LLL12 produces both
antiproliferative and proapoptotic effects. LLL12 should be a suitable
agent for targeting cancer cells with constitutively activated STAT3
owing to its ability to inhibit STAT3 phosphorylation and its potent
Figure 9. Effect of LLL12 on tumor growth in mouse xenografts with MDA-MB-231 breast cancer cells (A) or U87 glioblastoma cells (B).
After tumor development, the mice were given daily intraperitoneal dosages of 2.5 to 5 mg/kg LLL12 or DMSO (*P< .05). STAT3 but not
ERK1/2 phosphorylation of MDA-MB-231 tumor tissue samples from these mice was also decreased (C).
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growth-suppressive activity. Thus, LLL12 has the potential to be a
therapeutic agent for the treatment of human breast and pancreatic
cancer as well as glioblastoma with constitutively activated STAT3.
We also observed that LLL12 is a potent inhibitor of STAT3 phos-
phorylation and DNA binding activity in cancer cells from other can-
cer types such as colorectal and liver cancers (data not shown).
Therefore, LLL12 should be capable to have extended application
to inhibit other types of cancer cells that have constitutively activated
STAT3. LLL12 shows potential as a cancer therapeutic and is de-
served for further exploration of its use as a potential agent in the
treatment of cancer.
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Table W1. DNA Sequences of Primers of STAT3 Downstream Target Genes (Cyclin D1, Survivin,
Bcl-XL, and Bcl-2) Used for RT-PCR Analysis.
Gene Primers Size (bp) Source
Cyclin D1 Forward: 5′-GTGGAGCCCGTGAAAAAGA-3′ 247 [1]
Reverse: 5′-CTCCGCCTCTCGGCATTTG-3′
Survivin Forward: 5′-ACCAGGTGAGAAGTGAGGGA-3′ 309 [2]
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Bcl-XL Forward: 5′-TTGGACAATGGACTGGTTGA-3′ 765 [4]
Reverse: 5′-GTAGAGTGGATGGTCAGTG-3′
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Reverse: 5′-TCCTTGGAGGCCATGTGGGCAT-3′
GADPH indicates glyceraldehyde-3-phosphate dehydrogenase.
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Figure W1. LLL12 inhibits STAT3 phosphorylation, downregulates STAT3 downstream target genes (cyclin D1, survivin, and Bcl-2) ex-
pression, and induces apoptosis in (A) PANC-1 pancreatic cancer cells and (B) U373 glioblastoma cells.
